[Skip to Navigation]
Sign In
Views 460
Citations 0
Comment & Response
August 15, 2019

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer

Author Affiliations
  • 1Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
  • 2Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano, Milano, Italy
  • 3Precision Oncology, IFOM-FIRC Institute of Molecular Oncology, Milan, Italy
JAMA Oncol. 2019;5(10):1510-1511. doi:10.1001/jamaoncol.2019.2982

To the Editor Bregni et al1 reinterpreted the therapeutic history of 27 patients with ERBB2-amplified (referred to as “HER2-amplified” by the authors, but herein referred to as “ERBB2-amplified”) metastatic colorectal cancer (mCRC) in our HERACLES trial,2 concluding that ERBB2-amplification is not a biomarker of resistance to epidermal growth factor receptor (EGFR) inhibitors, thus suggesting that ERBB2 positivity screening (and anti-HER2 treatment) should be withheld until resistance to these agents has been proven. We are obliged to JAMA Oncology for this opportunity to argue otherwise and corroborate the value of ERBB2 screening in the treatment algorithm of mCRC.

Add or change institution